Zymeworks/$ZYME
Zymeworks gains after reporting Q3 EPS loss of $0.26, narrower than the $0.33 consensus estimate.
10 hours agoLightyear AI
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Zymeworks
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Ticker
$ZYME
Sector
Primary listing
Employees
263
Headquarters
Website
Zymeworks Metrics
BasicAdvanced
$1.4B
-
-$0.84
1.31
-
Price and volume
Market cap
$1.4B
Beta
1.31
52-week high
$19.98
52-week low
$9.03
Average daily volume
849K
Financial strength
Current ratio
6.938
Quick ratio
6.69
Long term debt to equity
4.844
Total debt to equity
5.906
Profitability
EBITDA (TTM)
-60.973
Gross margin (TTM)
-6.21%
Net profit margin (TTM)
-47.16%
Operating margin (TTM)
-52.51%
Effective tax rate (TTM)
-13.13%
Revenue per employee (TTM)
$510,000
Management effectiveness
Return on assets (TTM)
-9.98%
Return on equity (TTM)
-18.46%
Valuation
Price to revenue (TTM)
10.098
Price to book
4.24
Price to tangible book (TTM)
4.42
Price to free cash flow (TTM)
-20.517
Free cash flow yield (TTM)
-4.87%
Free cash flow per share (TTM)
-0.88
Growth
Revenue change (TTM)
116.21%
Earnings per share change (TTM)
-44.45%
3-year revenue growth (CAGR)
65.14%
3-year earnings per share growth (CAGR)
-39.55%
What the Analysts think about Zymeworks
Analyst ratings (Buy, Hold, Sell) for Zymeworks stock.
Bulls say / Bears say
Zanidatamab has received accelerated FDA approval, conditional NMPA approval in China and conditional marketing authorization by the European Commission in 2025, making it the first and only dual HER2‐targeted bispecific antibody approved for BTC in the U.S., Europe and China. (GlobeNewswire)
The European Commission granted conditional marketing authorization for Ziihera® on July 1, 2025, based on positive Phase 2b HERIZON-BTC-01 trial results, paving the way for EU commercial launch. (PRNewswire)
Q3 2025 total revenue was $27.6 million, up from $16.0 million in 3Q-2024, primarily driven by a $25.0 million milestone payment from J&J, underscoring the strength of its partnership-based revenue model. (GlobeNewswire)
Cash resources fell to $299.4 million as of September 30, 2025 from $324.2 million at December 31, 2024, reflecting continued cash burn and reliance on milestone receipts to fund operations. (GlobeNewswire)
Operating expenses of $49.7 million in 3Q 2025, including $35.6 million in R&D, exceeded revenue of $27.6 million, indicating persistent operational losses. (GlobeNewswire)
Royalties from Ziihera® net product sales were only $1.0 million in 3Q 2025, suggesting limited initial commercial traction despite regulatory approvals. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 7 Nov 2025.
Zymeworks Financial Performance
Revenues and expenses
Zymeworks Earnings Performance
Company profitability
Zymeworks News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Zymeworks stock?
Zymeworks (ZYME) has a market cap of $1.4B as of November 12, 2025.
What is the P/E ratio for Zymeworks stock?
The price to earnings (P/E) ratio for Zymeworks (ZYME) stock is 0 as of November 12, 2025.
Does Zymeworks stock pay dividends?
No, Zymeworks (ZYME) stock does not pay dividends to its shareholders as of November 12, 2025.
When is the next Zymeworks dividend payment date?
Zymeworks (ZYME) stock does not pay dividends to its shareholders.
What is the beta indicator for Zymeworks?
Zymeworks (ZYME) has a beta rating of 1.31. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.